{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:46:53Z","timestamp":1791712013148,"version":"4.3.4"},"reference-count":34,"publisher":"Rambam Health Corporation","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rambam Maimonides Med J"],"DOI":"10.5041\/rmmj.10169","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T05:23:19Z","timestamp":1414560199000},"page":"e0035","source":"Crossref","is-referenced-by-count":22,"title":["Calreticulin Mutations in Myeloproliferative Neoplasms"],"prefix":"10.5041","volume":"5","author":[{"given":"Noa","family":"Lavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2983","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","unstructured":"1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.","journal-title":"Nature"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","unstructured":"2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","unstructured":"3. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","unstructured":"4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"PJ","year":"2006","unstructured":"5. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","unstructured":"6. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011;118:1723-35.","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","unstructured":"7. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379-90.","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","unstructured":"8. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013;369: 2391-405.","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","unstructured":"9. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544-51.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","unstructured":"10. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014;123:1552-5.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/leu.2013.382","article-title":"Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis","volume":"28","author":"Chi","year":"2014","unstructured":"11. Chi J, Nicolaou KA, Nicolaidou V, et al. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 2014;28:1152-4.","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bjh.12969","article-title":"JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort","volume":"167","author":"McGaffin","year":"2014","unstructured":"12. McGaffin G, Harper K, Stirling D, McLintock L. JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol 2014;167:276-8.","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","unstructured":"13. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014;28:1472-7.","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","unstructured":"14. Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014;123: 2220-8.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","unstructured":"15. Michalak M, Groenendyk J, Szabo E, et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009;417:651-66.","journal-title":"Biochem J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.biocel.2012.02.009","article-title":"Calreticulin signaling in health and disease","volume":"44","author":"Wang","year":"2012","unstructured":"16. Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol 2012;44:842-6.","journal-title":"Int J Biochem Cell Biol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","unstructured":"17. Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J 2010;24:665-83.","journal-title":"FASEB J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","unstructured":"18. Chao MP, Weissman IL, Majeti R. The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 2012;24:225-32.","journal-title":"Curr Opin Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","unstructured":"19. Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012;12:860-75.","journal-title":"Nat Rev Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/onc.2012.130","article-title":"The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies","volume":"32","author":"Luo","year":"2013","unstructured":"20. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013;32:805-18.","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/leu.2014.33","article-title":"Looking for CALR mutations in familial myeloproliferative neoplasms","volume":"28","author":"Maffioli","year":"2014","unstructured":"21. Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia 2014;28:1357-60.","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014 May 5. [Epub ahead of print]","DOI":"10.1038\/leu.2014.148"},{"key":"ref22","unstructured":"23. Haslam K, Langabeer SE. Incidence of CALR mutations in patients with splanchnic vein thrombosis. Br J Haematol 2014 May 5. [Epub ahead of print]"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","unstructured":"24. Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014;28:1494-500.","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","unstructured":"25. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 2014;28:1568-70.","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/asheducation.V2012.1.561.3807838","article-title":"The spectrum of JAK2-positive myeloproliferative neoplasms","volume":"2012","author":"Kiladjian","year":"2012","unstructured":"26. Kiladjian JJ. The spectrum of JAK2-positive myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012;2012:561-6.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrclinonc.2014.16","article-title":"Genetics: CALR mutations and a new diagnostic algorithm for MPN","volume":"11","author":"Tefferi","year":"2014","unstructured":"27. Tefferi A, Pardanani A. Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 2014;11:125-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2014.35","article-title":"An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms","volume":"28","author":"Tefferi","year":"2014","unstructured":"28. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014;28: 1407-13.","journal-title":"Leukemia"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000358580","article-title":"Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond","volume":"133","author":"Michiels","year":"2014","unstructured":"29. Michiels JJ, Berneman Z, Schroyens W, De Raeve H. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Acta Haematol 2014;133:36-51.","journal-title":"Acta Haematol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","unstructured":"30. Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med 2014;371:188-9.","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","unstructured":"31. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366: 787-98.","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","unstructured":"32. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Cazzola M, Kralovics R. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014;370:1169.","DOI":"10.1056\/NEJMc1400499"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1002\/ajh.23703","article-title":"Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Tefferi","year":"2014","unstructured":"34. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:915-25.","journal-title":"Am J Hematol"}],"container-title":["Rambam Maimonides Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.rmmj.org.il\/userimages\/417\/1\/PublishFiles\/432Article.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T09:01:50Z","timestamp":1791709310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.rmmj.org.il\/issues\/23\/Articles\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,10,29]]}},"URL":"https:\/\/doi.org\/10.5041\/rmmj.10169","relation":{},"ISSN":["2076-9172"],"issn-type":[{"value":"2076-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]}}}